VRAY - ViewRay Stock Trading

ViewRay Inc.(NASDAQ: VRAY) stock trading, description, contact, officers and directors.

About ViewRay Inc.

ViewRay Incorporated of Cleveland, Ohio, is a privately held medical device company developing a simultaneous MRI guided adaptive radiation therapy technology for the treatment of cancer. With the ViewRay system, physicians have more control over the delivery of their radiation therapy prescriptions. ViewRay technology provides continuous soft tissue imaging during treatment, using MRI guided radiation therapy, so that clinicians can see the target, monitor the radiation dose, and adapt to changes in the patient s anatomy all in real time.

Stock Information

ViewRay Inc. Company Name:

VRAY Stock Symbol:

NASDAQ Market:

ViewRay Inc. Website:

VRAY - ViewRay Stock Trading

VRAY VRAY Quote VRAY Short VRAY News VRAY Articles VRAY Message Board

Get VRAY Alerts

News, Short Squeeze, Breakout and More Instantly...

VRAY - ViewRay's MRIdian suggests low incidence of toxicity in long term study

European Urology Oncology Journal published additional outcome from ViewRay's ( VRAY -4.9% ) prospective phase II study of MR-guided radiation therapy (MRgRT) in patients with localized prostate cancer. More news on: ViewRay, Inc., Healthcare stocks news, Read more ...
VRAY - ViewRay Announces 1-Year Outcomes on MR-Guided Radiation Treatment for Prostate Cancer Without Implanted Markers

CLEVELAND , June 23, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today the publication by the European Urology Oncology Journal of a prospective phase II study of MR-guided radiation therapy (MRgRT) in patients with localized prostate cancer. The publication is a foll...
VRAY - Week 24 MDA Breakout Forecast: Short-Term Stocks To Give You An Edge

Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 160 weeks of public selections as part of this ongoing live forward-testing resea...